Overdose of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in an HIV-1-infected subject with attempted suicide | Fundació Lluita contra la Sida

Recerca

Docència

PUBLICACIONS CIENTÍFIQUES > Overdose of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in an HIV-1-infected subject with attempted suicide

Overdose of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in an HIV-1-infected subject with attempted suicide

01/02/2019

Autors: Álvarez H, Mariño A, Valcarce N, García-González J, Díaz-Cambre H, Llibre JM.

Revista: Infection.

Abstract

INTRODUCTION: Data are lacking regarding overdose of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF).

MATERIAL AND METHODS: We present the first report of suicidal attempt with E/C/F/TAF in a Human Immunodeficiency Virus-infected subject.

RESULTS: A reversible acute renal failure with no proximal tubulopathy and neuropsychiatric issues are discussed. E/C/F/TAF withdrawal resulted in favourable renal and neuropsychiatric outcomes. The suicide attempt seemed unrelated to the integrase strand transfer inhibitor, being evenly explained within the context of stressful personal conflicts.

CONCLUSION: A suicidal attempt with an E/C/F/TAF overdose in an HIV-infected patient, resulted in a favourable outcome from a renal and neuropsychiatric standpoint.